Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what data his Department holds on the effectiveness of the (a) Pfizer, (b) AstraZeneca and (c) Moderna covid-19 vaccinations at reducing transmission of covid-19.
Public Health England (PHE) publishes weekly COVID-19 vaccine surveillance reports which include the latest evidence on vaccine effectiveness against different outcomes. The following table shows the latest summary of evidence on vaccine effectiveness against different outcomes, including transmission, for Pfizer/BioNTech and University of Oxford/AstraZeneca as of 1 July.
Outcome | Vaccine Effectiveness | |||
Pfizer/BioNTech | Oxford/AstraZeneca | |||
1 dose | 2 doses | 1 dose | 2 doses | |
Symptomatic disease | 55-70%* | 85-95%* | 55-70%* | 70-85%** |
Hospitalisation | 75-85%* | 90-99%** | 75-85%* | 80-99%*** |
Mortality | 70-80%** | 95-99%** | 75-85%** | 75-99%*** |
Infection | 55-70%** | 70-90%*** | 60-70%*** | No data |
Transmission (secondary cases)^ | 45-50%*** | No data | 35-50%*** | No data |
Source: Table 3 https://www.gov.uk/government/publications/covid-19-vaccine-surveillance-report
Notes:
PHE plans to publish vaccine effectiveness data for Moderna when more evidence becomes available.